Product Description
Cyclophosphamide is used to treat cancer of the ovaries, breast, blood and lymph system, and nerves (mainly in children). Cyclophosphamide is also used for retinoblastoma (a type of eye cancer mainly in children), multiple myeloma (cancer in the bone marrow), and mycosis fungoides (tumors on the skin). (Sourced from: https://www.mayoclinic.org/drugs-supplements/cyclophosphamide-oral-route-intravenous-route/description/drg-20063307)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Breast Diseases | Hodgkin Lymphoma | Leukemia | Lymphoid Leukemia | Lymphoma | Multiple Myeloma | Mycosis Fungoides | Breast Cancer | Neuroblastoma | Retinoblastoma | Oncology Unspecified | Nephrotic Syndrome | Burkitt Lymphoma | Heart Failure | Myocarditis | Pericardial Effusion | Pulmonary Heart Disease | Alopecia | Breast Diseases | Liver Cirrhosis | Liver Failure | Febrile Neutropenia | Neutropenia | Hodgkin Lymphoma | Leukemia | Lymphoid Leukemia | Lymphoma | Multiple Myeloma | Mycosis Fungoides | Breast Cancer | Neuroblastoma | Pulmonary Blastoma | Retinoblastoma | Oncology Unspecified | Pregnancy Outcomes | Fetal Diseases | Nephrotic Syndrome | Pulmonary Fibrosis | Pulmonary Veno-Occlusive Disease | Respiratory Insufficiency | Diarrhea | Burkitt Lymphoma | Breast Diseases | Hodgkin Lymphoma | Leukemia | Lymphoid Leukemia | Lymphoma | Multiple Myeloma | Mycosis Fungoides | Adenocarcinoma | Breast Cancer | Neuroblastoma | Retinoblastoma | Oncology Unspecified | Burkitt Lymphoma
Known Adverse Events: Alopecia | Febrile Neutropenia | Neutropenia | Diarrhea | Kidney Diseases | Cardiac Arrhythmias | Heart Failure | Myocarditis | Pericardial Effusion | Pericarditis | Pulmonary Heart Disease | Liver Cirrhosis | Liver Failure | Contraception | Pulmonary Fibrosis | Pulmonary Veno-Occlusive Disease | Respiratory Insufficiency | Signs and Symptoms, Respiratory
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Russia, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 69
Highest Development Phases
Phase 3: Amyloidosis|Breast Cancer|Lymphoma, Non-Hodgkin|Sarcoma|T-Cell Peripheral Lymphoma
Phase 2: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|B-Cell Marginal Zone Lymphoma|Bladder Cancer|Blood Protein Disorders|Chronic Lymphoid Leukemia|Colorectal Cancer|Diffuse Large B-Cell Lymphoma|Epstein-Barr Virus Infections|Fallopian Tube Cancer|Follicular Lymphoma|Glioma|Graft vs Host Disease|Hepatocellular Carcinoma|Hodgkin Lymphoma|Inflammatory Breast Cancer|Kidney Diseases|Leukemia, Plasma Cell|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Mantle-Cell Lymphoma|Melanoma|Monoclonal Gammopathy of Undetermined Significance|Multiple Myeloma|Myelodysplastic Syndrome|Neuroblastoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Paraproteinemias|Peritoneal Cancer|Plasmacytoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Primary Central Nervous System Lymphoma|Pseudomyxoma Peritonei|Sarcoma, Ewing|Stem Cell Transplant|T-Cell Lymphoma|Triple Negative Breast Cancer|Waldenstrom Macroglobulinemia
Phase 1: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Adenocarcinoma|Biphenotypic Acute Leukemia|Brain Stem Cancer|COVID-19|Central Nervous System Cancer|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Juvenile Myelomonocytic Leukemia,|Liver Cancer|Lupus Erythematosus, Systemic|Lymphoid Leukemia|Medulloblastoma|Mesothelioma|Myeloproliferative Disorders|Oncology Solid Tumor Unspecified|Osteosarcoma|Pancreatic Cancer|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Prostate Cancer|Relapsed/Refractory Lymphoma|Small Cell Lung Cancer|Soft Tissue Cancer|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TROPIKANA | P1 |
Recruiting |
Small Cell Lung Cancer|Breast Cancer|Non-Small-Cell Lung Cancer |
2038-04-30 |
|
| HEM-iSMART B | P2 |
Not yet recruiting |
Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2031-10-01 |
|
| HEM-iSMART C | P2 |
Not yet recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin |
2031-10-01 |
|
| CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |